Hypogonadism, Male Clinical Trial
— Sal TOfficial title:
Salivary Testosterone in Men: Diurnal Variation and Post-prandial Responses
Verified date | May 2024 |
Source | The Royal Wolverhampton Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose is to evaluate Sal-T against standard biomarkers of male gonadal status based on serum T, calculated free T and BAT. The optimal salivary sampling in terms of fasting and time of day will also be defined. The ultimate aim is to add Sal-T into the Trust's repertoire of tests in investigating suspected hypogonadism in men.
Status | Completed |
Enrollment | 40 |
Est. completion date | October 30, 2023 |
Est. primary completion date | October 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 20 Years to 60 Years |
Eligibility | For 1st part of study -volunteers: Inclusion Criteria: - Aged 20-60 years - Male Exclusion Criteria: - Subjects with learning disability or those lacking mental capacity to give consent. - On (prescribed and over-the-counter) medication and herbal remedies known to affect androgen metabolism. - Known hypogonadism. - Conditions known to affect androgen metabolism, including chronic inflammatory diseases, chronic liver disease, chronic kidney disease and thyroid dysfunction. - Any co-morbidity. - Periodontal disease. - Dental work 48 hours prior to the test. - Exercise on the day, prior to and during sampling periods. - Brushed teeth within 1hr prior to sample collection. - Obesity defined as a body mass index (BMI) of greater than 29.9 kg/m2As 2nd part of study for glucose load - oral glucose tolerance test (OGTT): Inclusion criteria: - Aged over 40-60 years. - Attending for routine 75 g OGTT Exclusion criteria: - Subjects with learning disability or lacking mental capacity to give consent. - On (prescribed and over-the-counter) medication and herbal remedies known to affect androgen metabolism. - Known hypogonadism. - Conditions known to affect androgen metabolism, including chronic inflammatory diseases, chronic liver disease, chronic kidney disease and thyroid dysfunction. - Subjects with difficult venous access. - Periodontal disease. - Dental work 48 hours prior to the test. - Brushed teeth within 1hour prior to sample collection. - Exercise on day prior to and during the OGTT. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Royal Wolverhampton NHS Trust | Wolverhampton | West Midlands |
Lead Sponsor | Collaborator |
---|---|
The Royal Wolverhampton Hospitals NHS Trust |
United Kingdom,
Fenn J, Gill H, Starbrook L, Ford LT, Sharrod-Cole H, Kalaria T, Ford C, Gama R. Salivary testosterone changes during oral glucose tolerance tests in overweight and obese men - postprandial or circadian variation? Ann Clin Biochem. 2024 Apr 9:456322412490 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in salivary testosterone during the day independent of prandial state | testosterone levels | 24 hours | |
Primary | Changes in salivary testosterone following an oral glucose load | testosterone levels | 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04467697 -
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
|
Phase 3 | |
Completed |
NCT03203681 -
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
|
Phase 4 | |
Completed |
NCT01904734 -
Clomid in Men With Low Testosterone With and Without Prior Treatment
|
Phase 2 | |
Completed |
NCT00398580 -
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
|
Phase 2 | |
Completed |
NCT00400335 -
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
|
Phase 1 | |
Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
Completed |
NCT03282682 -
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
|
N/A | |
Terminated |
NCT03335254 -
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
|
Phase 1/Phase 2 | |
Terminated |
NCT05205837 -
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
|
Phase 4 | |
Completed |
NCT03747003 -
Gonadal Function in Young to Middle Aged HIV-infected Men
|
||
Withdrawn |
NCT03176537 -
Periodontal Profile of Hypogonadic Men
|
Phase 4 | |
Recruiting |
NCT04049331 -
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
|
Phase 2 | |
Completed |
NCT03541395 -
Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
|
N/A | |
Recruiting |
NCT05249634 -
Testosterone Treatment in Men With Chronic Kidney Disease
|
Phase 2 | |
Not yet recruiting |
NCT05773183 -
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
|
||
Withdrawn |
NCT04717362 -
The Effects of Natesto For Treatment Of Hypogonadism
|
Early Phase 1 | |
Completed |
NCT05806723 -
Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men
|
Phase 4 | |
Completed |
NCT04456296 -
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
|
Phase 4 | |
Not yet recruiting |
NCT06312761 -
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
|
Phase 1/Phase 2 | |
Recruiting |
NCT05381831 -
Natesto Spermatogenesis Reboot
|
Phase 4 |